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Objectives The aim of this study was to determine whether activation of 3-adrenergic receptor (AR) and downstream sig-
naling of nitric oxide synthase (NOS) isoforms protects the heart from failure and hypertrophy induced by pres-
sure overload.
Background 3-AR and its downstream signaling pathways are recognized as novel modulators of heart function. Unlike
1- and 2-ARs, 3-ARs are stimulated at high catecholamine concentrations and induce negative inotropic ef-
fects, serving as a “brake” to protect the heart from catecholamine overstimulation.
Methods C57BL/6J and neuronal NOS (nNOS) knockout mice were assigned to receive transverse aortic constriction
(TAC), BRL37344 (3 agonist, BRL 0.1 mg/kg/h), or both.
Results Three weeks of BRL treatment in wild-type mice attenuated left ventricular dilation and systolic dysfunction, and
partially reduced cardiac hypertrophy induced by TAC. This effect was associated with increased nitric oxide pro-
duction and superoxide suppression. TAC decreased endothelial NOS (eNOS) dimerization, indicating eNOS un-
coupling, which was not reversed by BRL treatment. However, nNOS protein expression was up-regulated 2-fold
by BRL, and the suppressive effect of BRL on superoxide generation was abrogated by acute nNOS inhibition.
Furthermore, BRL cardioprotective effects were actually detrimental in nNOS–/– mice.
Conclusions These results are the first to show in vivo cardioprotective effects of 3-AR–specific agonism in pressure over-
load hypertrophy and heart failure, and support nNOS as the primary downstream NOS isoform in maintaining
NO and reactive oxygen species balance in the failing heart. (J Am Coll Cardiol 2012;59:1979–87) © 2012 by
the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.046There is accumulating evidence that 3-adrenergic recep-
tors (3-AR) play an important role in the modulation of
ardiovascular function in heart failure (1–3). In contrast to
he well-characterized 1/2-AR, stimulation of 3-AR
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2011, accepted December 1, 2011.induces a negative inotropic effect that is associated with
nitric oxide (NO) release via nitric oxide synthase (NOS)
activation (4). Chronic heart failure is associated with
sustained overactivation of the sympathetic nervous system,
which initially plays a compensatory role for depressed
contractility, but worsens heart function over time. The
positive inotropic response to -AR stimulation is dimin-
See page 1988
ished during heart failure due to selective down-regulation
and desensitization of 1/2-AR (5). Conversely, 3-AR is
up-regulated in failing hearts in both human and animal
models (6–8). Whether this increase is a protective re-
sponse to catecholamine overexpression or a contributor to
heart failure has been controversial; however, increasing
evidence suggests it functions as a “physiological brake” to
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3-AR Prevents Cardiac Dysfunction Through nNOS May 29, 2012:1979–87reduce the effects of sympathetic
overstimulation. Belge et al. (9)
showed that mice with cardiomy-
ocyte-specific overexpression of
3-AR had attenuated left ven-
tricular (LV) hypertrophy com-
pared with wild-type (WT) mice
in response to chronic isoprena-
line administration. Our recent
work revealed exacerbated path-
ological remodeling and im-
paired cardiac functional com-
pensation in mice lacking 3-AR
(2,10). These studies support the
idea that 3-AR serves a chiefly
protective role in maladaptive re-
modeling and in the develop-
ment of heart failure.
It is well established that the
negative inotropic effect of 3-AR
results from the downstream
production of NO by NOS sig-
naling (4,11). The effects of a 3
agonist, BRL 37344 (BRL),
were inhibited by both NO and
NOS inhibitors and could be re-
ersed by an excess of the substrate for NO production,
-arginine. Several studies have suggested that endothelial
OS (eNOS) is solely responsible for 3-induced negative
inotropy (4,11–13). However, the relative involvement of
neuronal NOS (nNOS), which is also constitutively ex-
pressed in cardiomyocytes, still remains unclear. Alterations
of NOS-dependent regulation on cardiac function make
this issue more complex. There is an apparent paradox
between the observation that 3-AR stimulation induces an
O-dependent negative inotropic effect on failing ventricular
yocardium despite the finding that eNOS-derived NO is
ecreased in this setting (14). These inconsistent findings may
e reconciled by recent evidence indicating that nNOS-derived
O production was involved in altered contractile response by
3-AR stimulation in both diabetic and senescent hearts
(15,16).
In the present study, we hypothesized that the 3-AR
preferential agonist BRL could reduce cardiac remodeling
induced by pressure overload and preserve cardiac function
through NO production, which may be largely attributable
to activation of nNOS.
Methods
Experimental model. Thirty-eight C57BL/6J and 12
nNOS–/–/B6129S male mice (9 to 10 weeks old; Jackson
aboratory, Bar Harbor, Maine) were arbitrarily divided
nto 3 groups. Two-thirds of the mice underwent transverse
ortic constriction (TAC) to induce cardiac hypertrophy
Abbreviations
and Acronyms
AR  adrenergic receptor
BRL  (()-(R*,R*)-[4-[2-
[[2-(3-chlorophenyl)-2-
hydroxyethyl]amino]propyl]
phenoxy]acetic acid
sodium
eNOS  endothelial nitric
oxide synthase
EPR  electron
paramagnetic resonance
LV  left ventricular
nNOS  neuronal nitric
oxide synthase
NO  nitric oxide
NOS  nitric oxide
synthase
ROS  reactive oxygen
species
TAC  transverse aortic
constriction
WT  wild-type
XOR  xanthine
oxidoreductasend heart failure via pressure overload (17), while theemaining one-third had a sham procedure (Online
ppendix).
ardiac function and geometry. In vivo cardiac geometry
nd function were serially assessed by transthoracic echo-
ardiography (Acuson Sequoia C256, 13 MHz transducer,
iemens, Oceanside, California) in conscious mice at base-
ine, 1 week, and 3 weeks.
istological evaluation and cellular morphometry.
yocardium was fixed in 10% formalin, processed by standard
araffin embedding, and serially sectioned at 5 to 8 m
hickness for hematoxylin and eosin and trichrome staining.
easurement of cardiac NO production. Cardiac NO
roduction was determined as the measurement of nitrate
lus nitrite using the Griess reaction assay (Cayman Chem-
cal, Ann Arbor, Michigan) as previously described (18).
easurement of cardiac superoxide generation. LUCIGENIN-
ENHANCED CHEMILUMINESCENCE. Fresh-frozen myocar-
dium was homogenized in 20 mol/l HEPES buffer and
diluted in lucigenin buffer. Superoxide-generated signals
were recorded as counts per minute (CPM) by a liquid
scintillation counter (LS6000IC, Beckman Instruments,
Fullerton, California).
ELECTRON PARAMAGNETIC RESONANCE. Fresh-frozen
myocardium was homogenized in 1 phosphate buffer
saline (PBS) containing 0.1 mM diethylenetriaminepenta-acetic
acid (DTPA) (Sigma Aldrich, St. Louis, Missouri). Samples
were further diluted in 1 PBS with 1 mM 1-hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethyl pyrrolidine (CMH)
(Enzo Life Sciences, Farmingdale, New York) and as-
sayed for superoxide signals by Bruker E-Scan (Billerica,
Massachusetts) electron paramagnetic resonance (EPR)
spectrometer.
Western blot analysis. Snap-frozen LV tissue was homog-
enized in cell lysis buffer (Cell Signaling Technology,
Danvers, Massachusetts) and subjected to Western blot
analysis with antibodies targeting the protein of interest.
The densitometric volume of digitalized bands was evalu-
ated by the Image J program version 1.44p (National
Institutes of Health, Bethesda, Maryland).
Statistical analysis. All data are expressed as mean 
standard error of the mean. Echocardiographic data were
compared using repeated measures analysis of variance.
Group data were compared using 1-way analysis of variance
with Tukey’s post hoc test for multiple comparisons. Stu-
dent t test with Welsh correction for multiple comparisons
as used to compare the difference between BRL and
ehicle-treated nNOS–/– mice. All p values 0.05 were
considered to be statistically significant. GraphPad Prism
5.0 (La Jolla, California) was used for statistical analysis.
Results
3-AR stimulation prevents deterioration of cardiac
function. Mice developed increased LV chamber dilation
and systolic dysfunction after 3 weeks of TAC (Fig. 1A), as
evidenced by an 82% increase in LV end-systolic diameter and
1981JACC Vol. 59, No. 22, 2012 Niu et al.
May 29, 2012:1979–87 3-AR Prevents Cardiac Dysfunction Through nNOSa 36% reduction in fractional shortening (FS%) compared with
sham mice by echocardiography (Figs. 1B and 1C). Calculated
LV mass and average wall thickness were increased versus
sham (Fig. 1D). Three weeks of BRL treatment totally
prevented LV dilation, and cardiac systolic function remained
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(A) M-mode echocardiograms demonstrating increased left ventricular (LV) dilation
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3-AR Prevents Cardiac Dysfunction Through nNOS May 29, 2012:1979–87body weight ratio. BRL-treated mice developed less hyper-
trophy (Online Fig. 1A). These findings were paralleled by
similar changes in calculated LV mass by echocardiography
(Fig. 1D). Both cardiomyocyte width by hematoxylin and
eosin staining and fibrosis scale (0 to 3 scale: 0  none, 3 
severe) by trichrome staining were significantly greater in
TAC versus sham. Interestingly, BRL reduced cardiomyo-
cyte width but had no effect on fibrosis scale (Online Figs.
1B and 1C).
3-AR stimulation increases cardiac NO production and
decreases reactive oxygen species production in pressure-
overloaded mice. 3-AR–induced negative inotropic ef-
ects are thought to be associated with NO release via NOS
4). Our previous data showed that mice lacking 3-AR had
lower NOS activity and generated more cardiac superoxide
than WT mice after pressure overload (2). We, therefore,
tested NO production by measuring the sum concentrations
of the NO metabolites (nitrate and nitrite) using the Griess
assay and superoxide generation by lucigenin-enhanced
chemiluminescence and EPR to observe the effect of 3-AR
gonism on NO and reactive oxygen species (ROS) produc-
ion. Total nitrate  nitrite concentrations were decreased
y 50% (Fig. 2A) and superoxide was increased 3.5-fold
Fig. 2B) in TAC hearts over sham controls. Three weeks of
RL treatment completely prevented this decrease in NO
etabolite concentration and partially inhibited superoxide
eneration. Superoxide studies were confirmed using EPR,
hich showed a 1.5-fold increase in ROS generation
Fig. 2C) and a downward trend in ROS production with
RL administration.
3-AR stimulation regulates nNOS protein expression
and superoxide generation. Recent studies demonstrated
that nNOS-derived NO production was involved in altered
contractile response by 3-AR stimulation in both diabetic
and senescent hearts (15,16). We observed a 2-fold increase
in nNOS protein expression in BRL-treated compared with
vehicle-treated hearts (Fig. 3A), although there was no
difference between sham and untreated TAC. More inter-
estingly, pre-treating LV homogenates with 100 nM of the
specific nNOS inhibitor vinyl-L-NIO (L-VNIO) com-
pletely abolished BRL suppression of superoxide generation
(Fig. 3B). This suggests that 3-AR reduces superoxide
generation via an nNOS-dependent mechanism in the
failing heart.
BRL modulation of eNOS and inducible NOS activation.
To investigate further the role of BRL on other NOS
isoforms, we examined eNOS protein expression and
phosphorylation. We focused on 3 enzyme phosphorylation
sites that have been shown to modulate eNOS activity in the
myocardium (19): eNOSSer1177, eNOSSer114, and eNOSThr495.
fter 3 weeks of TACBRL treatment, eNOSSer1177
phosphorylation, which indicates eNOS activation, was
decreased by 50% as compared with TAC alone. In contrast,
phosphorylation of eNOSSer114, which is an indication of
eNOS deactivation, was increased 100% in BRL-treated
mice, whereas levels were similar between sham and un- utreated TAC (Fig. 4A). Total eNOS protein expression
(Fig. 4A) and eNOSThr495 phosphorylation were unchanged
etween groups (Online Fig. 2A). In addition, no difference
n inducible NOS expression was observed between groups
Online Fig. 2B).
eNOS monomer-to-dimer ratio is an indication of eNOS
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Figure 2 Changes in NO Production and Superoxide Genera-
tion by BRL Treatment
(A) Nitric oxide (NO) production, measured by Griess assay, was decreased by
50% after 3 weeks of transverse aortic constriction (TAC), but preserved at nor-
mal levels in the presence of BRL. (B) Lucigenin-enhanced chemiluminescence
detected 3.5-fold increase in superoxide in 3-week TAC mice, which was signifi-
cantly reduced BRL administration. (C) Electron paramagnetic resonance (EPR)
detected a 1.5-fold increase in superoxide in TAC animals and downward trend
in TACBRL. *p  0.05 vs. sham. †p  0.01 vs. TAC. WT  wild type.ncoupling, which results in NO generation switching to
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May 29, 2012:1979–87 3-AR Prevents Cardiac Dysfunction Through nNOSsuperoxide generation. Our data show that 3 weeks of TAC
resulted in increased eNOS uncoupling, which is consis-
tent with previous reports (10,17,20), although 3 weeks
of BRL treatment did not change the monomer-to-dimer
ratio (Fig. 4B).
Lack of nNOS gene abolished the protective effect of
3-AR stimulation. Because nNOS protein expression
was up-regulated by BRL treatment, and BRL-induced
superoxide suppression was attenuated by acute nNOS
inhibition, we hypothesized that nNOS is pivotal in 3-
R–induced cardioprotection. To confirm this hypothesis,
e used the 3-week TAC model in the absence or presence
f BRL in mice genetically lacking nNOS. After 1 week,
AC mice developed LV systolic dysfunction (Fig. 5B) and
hamber dilation (Fig. 5C) as compared with sham nNOS–/–
mice. BRL treatment not only failed to restore LV function
and dilation to baseline levels after 3 weeks of pressure
overload, but also exacerbated dysfunction (Fig. 5B) and LV
dilation (Fig. 5C). LV mass (Fig. 5D) was 33% greater in
TAC nNOS–/– mice as compared with sham nNOS–/–, and
orse in TACBRL mice (Fig. 5D) as compared with
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Figure 3 Effect of BRL on nNOS Protein Expression and
the Superoxide Generation by Acute nNOS Inhibition
(A) Neuronal nitric oxide synthase (nNOS) protein expression was significantly
up-regulated by BRL treatment, though similar between sham and transverse
aortic constriction (TAC). (B) Acute nNOS inhibition (striped bars) abrogated
BRL-induced superoxide suppression in the presence of nNOS-specific inhibitor
L-VNIO, (100 uM, 30 min in cold room), as compared with non–L-VNIO treated
samples (open bars). *p  0.01 vs. sham. †p  0.05 vs. TAC. GAPDH 
glyceraldehyde 3-phosphate dehydrogenase.AC-alone mice. Wall thickness was also increased inAC nNOS–/– mice as compared with sham (Fig. 5D).
here was no difference in wall thickness among
RLTAC and TAC animals (Fig. 5D).
iscussion
he novel findings in this study are that 3-AR activation
revents cardiac dysfunction through generating NO and
educing ROS via an nNOS-dependent mechanism in the
ailing heart.
nduction of cardioprotection by 3-AR. Despite a low
evel of myocardial expression and physiological insignifi-
ance under resting conditions (21), accumulating literature
upports a significant role for 3-AR up-regulation in the
odulation of cardiac remodeling in heart failure. Until
ow, direct evidence in vivo has been lacking. We have
reviously compared the cardiac response to pressure over-
oad in both WT and 3–/– mice, displaying greater hyper-
trophy and cardiac systolic dysfunction in 3–/– mice as
ompared with WT controls (2). More recently, Arago´n et
l. demonstrated that select 3-AR agonists, including the
1-blocker nebivolol, reduced cardiac infarct size in mice
ubjected to myocardial ischemia and reperfusion in WT,
ut were completely ineffective in 3-AR– deficient mice
(22). In the current study, we confirm that 3-AR
gonism exerts a cardioprotective role in the failing heart
6,15,22,23). We observed that administering the 3-AR–
specific agonist BRL to C57BL/6 mice for 3 weeks totally
prevented the deterioration of LV chamber dilation and
cardiac dysfunction, and partially inhibited myocardial hy-
pertrophy induced by chronic pressure overload. This
strongly suggests that specific 3-AR agonism may consti-
ute an interesting and novel approach in treating cardiac
ypertrophy and heart failure.
rimary role of nNOS in 3-AR cardioprotection. Ear-
ier studies have suggested that the 3-AR–induced cardiac
signaling is associated with NO release via eNOS (4,11).
Chronic 3-AR stimulation in our model prevented the
xpected decrease in NO production during pressure over-
oad, which confirmed our previous findings that NOS
ctivity is decreased in 3–/– mice after TAC (2). Although
rior studies assumed that cardiac eNOS was the sole source
f NO involved in the regulation of myocardial contraction
4,11), there remains great controversy over which NOS
soform is the chief player in 3-AR signaling.
In the present study, eNOS and inducible NOS protein
expressions were unchanged by BRL treatment. eNOS
activity is generally modulated by either translocation or
phosphorylation. Translocation has been observed by
3-AR stimulation only in the right atrium, not in the left
ventricle (12,13). Ser1177 and Ser114 are 2 phosphorylation
sites that can modulate eNOS activity. Phosphorylation at
Ser1177 (or Ser1179 in humans) activates eNOS, whereas
phosphorylation at Ser114 deactivates eNOS (24–26). We
observed a decrease in Ser1177 phosphorylation and an
increase in Ser114 phosphorylation after BRL treatment,
s
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3-AR Prevents Cardiac Dysfunction Through nNOS May 29, 2012:1979–87which suggested eNOS deactivation rather than activation
by 3-AR stimulation. Similar results were recently ob-
erved in isolated human failing myocardium (14). The
pparent paradox between the known 3-AR–mediated
NO-dependent negative inotropic effect and clear eNOS
deactivation in human failing myocardium could be ex-
plained by concomitant nNOS activation in cardiomyo-
cytes. Paracrine negative inotropic effects via NO liberation
from cardiac endothelial cells may be another explanation,
but lacked in direct evidence until recently. The same group
also reported that eNOS was activated through Ser1177
phosphorylation by BRL in human nonfailing myocardium,
which identified differential downstream signaling by
3-AR stimulation between failing and nonfailing hearts
(12,13).
Emerging evidence indicates that nNOS-derived NO
production plays a substantial part in the regulation of basal
and -AR–induced myocardial contraction (27,28). nNOS
was up-regulated in senescent rat hearts after myocardial
infarction and in human failing hearts (22,27,29,30). Inter-
estingly, it was shown that the positive inotropic response to
nonspecific -AR stimulation was impaired in diabetic and
aged rat hearts and restored by a 3-AR antagonist, a
nonselective NOS inhibitor, and the selective nNOS inhib-
itor L-VNIO (15,16). nNOS gene deletion has been asso-
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striction (TAC) mice. (B) eNOS uncoupling indexed by increased eNOS monomer-to
*p  0.05 vs. sham. †p  0.05 vs. TAC.ciated with more severe LV remodeling and functionaldeterioration in murine models of myocardial infarction,
suggesting that nNOS-derived NO may also be involved in
a protective myocardial response to injury (18,31). The
present study revealed exclusive nNOS protein up-
regulation and activation by 3-AR agonism, suggesting
NOS-derived NO production is the primary source in the
ardioprotective effect of 3-AR agonism. Importantly,
cardiac hypertrophy, LV dysfunction, and reduced ejection
fraction induced by TAC were actually worsened by BRL
treatment in nNOS–/– mice, further confirming this mech-
nism. An ex vivo study from Idigo et al. also showed that
he negative inotropic response to BRL in cardiomyocytes
as absent in both nNOS–/– cardiomyocytes and WT
cardiomyocytes with pharmacological inhibition of nNOS
(32). These studies support nNOS-derived NO production
as a primary factor in altered contractile response by 3-AR
stimulation of the heart. We speculate that the pathway
regulating cardiac contractility may be associated with
nNOS post-translational modification such as translocation
from sarcoplasmic reticulum to sarcolemma (27) or phos-
phorylation of select residues (33). This merits further
investigation, and studies are ongoing in our laboratory.
Inhibition of oxidative stress. A significant number of
animal studies and several clinical observations have dem-
onstrated ROS activation in the cardiovascular system in
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May 29, 2012:1979–87 3-AR Prevents Cardiac Dysfunction Through nNOShypertrophic and failing heart (34–36). Biomarkers for
ROS have been detected in the pericardial fluid as well as in
the peripheral blood of heart failure patients (37). Further
experiments showed that ROS is increased in cardiac
hypertrophy and adverse remodeling (38,39). However, the
mechanism by which 3-AR stimulation affects ROS gen-
ration has not been clearly delineated. In our previous study
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(A) M-mode echocardiograms demonstrated increased LV dilation and wall thickne
BRL administration. (B) LV systolic function was decreased by TAC and worsened
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This was confirmed by the current study, which demon-
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3-AR Prevents Cardiac Dysfunction Through nNOS May 29, 2012:1979–87concentration that only inhibits nNOS without affecting
other NOS isoforms. These results revealed the antioxidant
effect of 3-AR agonism is dependent on nNOS activation.
Recently, Khan et al. (40) and Kinugawa et al. (41) have
shown that deficiency of nNOS leads to profound increase
in xanthine oxidoreductase (XOR)–mediated superoxide
production without affecting XOR mRNA or protein abun-
dance, which depresses myocardial excitation-contraction
coupling in a manner reversible by XOR inhibitor. This
suggests constrained XOR activity by nNOS as a possible
connection between myocardial NOS and ROS systems.
We observed that eNOS was uncoupled after 3 weeks of
TAC, which is in agreement with previous reports (17,20).
However, eNOS was not recoupled by BRL treatment,
providing further evidence that eNOS is not the sole
pathway for 3-AR, as previously thought. In addition,
BRL-induced eNOS-Ser114 phosphorylation could indi-
cate uncoupling and may explain the reason for exacerbated
dysfunction seen in TAC nNOS–/– animals treated with
RL. We speculate that 3-AR regulation occurs via
alancing 2 opposing pathways when the heart starts to fail:
deleterious eNOS-dependent pathway and a protective
NOS-dependent pathway. Thus, the cardioprotective ef-
ect of 3-AR agonism on cardiac hypertrophy and heart
ailure could be attributed to nNOS activation, which
aintains the equilibrium of myocardial NO and ROS
roduction, despite uncoupled eNOS in this setting.
linical implication. 1-blockers have become the stan-
ard treatment for chronic heart failure since 1990. We
ropose that 3-AR activation can be considered similar to
an endogenous 1-blocker, due to its protective and nega-
ive inotropic effect on human myocardium. This study
trongly supports the notion that 3-AR plays a beneficial
role in heart and highlights the potential therapeutic utility
of 3-AR agonism. Although low basal expression levels of
3-AR in some tissues have resulted in disappointing
outcomes from animal studies to clinical trials evaluating
3-AR agonists for obesity, type 2 diabetes, and irritable
bowel syndrome treatment (42–45), heart failure represents
a more realistic promising therapeutic target for 3 main
reasons. First, 3-AR has been demonstrated to be ex-
ressed at levels that can mediate physiological responses in
ealthy human myocardium (1). Second, 3-AR is up-
regulated 2- to 3-fold in the progression of heart failure,
whereas 1-AR is down-regulated (6). This increase in
3-AR/1-AR ratio likely plays a substantial role in acti-
vating 3-AR signaling. Lastly, cotreatment with conven-
ional -blockers can further increase the expression of
3-AR. A study in diabetic rats demonstrated that chronic
treatment with metoprolol markedly increased the expression
of cardiac 3-AR (46). Recent studies reported that the
emodynamic improvement obtained from third-generation
-blocker, nebivolol, in mice subjected to myocardial
schemia-reperfusion and heart failure patients is partially due
o its NO-dependent negative inotropic effect by 3-ARstimulation (22,47).Conclusions
We have shown that 3-specific agonism in vivo has
ubstantial cardioprotective effects, and that these effects are
argely attributable to nNOS activation. These findings have
irect therapeutic implications for treating heart failure
atients and for improving our understanding of the patho-
hysiology of heart failure.
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